Recent Analysts’ Ratings Changes for Agenus (AGEN)

Agenus (NASDAQ: AGEN) has recently received a number of price target changes and ratings updates:

• 3/21/2025 – Agenus was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 3/18/2025 – Agenus had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 3/12/2025 – Agenus had its price target lowered by analysts at Robert W. Baird from $6.00 to $3.00. They now have a “neutral” rating on the stock.
• 3/12/2025 – Agenus had its “neutral” rating reaffirmed by analysts at HC Wainwright.

Agenus Trading Up 1.3 %

NASDAQ AGEN traded up $0.02 on Wednesday, hitting $1.62. 114,420 shares of the stock traded hands, compared to its average volume of 616,616. The company has a market capitalization of $41.00 million, a P/E ratio of -0.14 and a beta of 1.23. The stock has a 50-day moving average of $2.76 and a 200 day moving average of $3.47. Agenus Inc. has a twelve month low of $1.44 and a twelve month high of $19.69.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The business had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million. As a group, equities research analysts expect that Agenus Inc. will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

A number of institutional investors have recently modified their holdings of AGEN. B. Riley Financial Inc. acquired a new position in Agenus in the fourth quarter valued at approximately $2,074,000. Gilead Sciences Inc. acquired a new position in Agenus during the 4th quarter valued at approximately $635,000. Walleye Capital LLC bought a new position in Agenus during the 3rd quarter worth $1,003,000. Jane Street Group LLC increased its position in Agenus by 97.6% in the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock worth $290,000 after buying an additional 52,215 shares during the period. Finally, Deutsche Bank AG lifted its stake in Agenus by 538.4% in the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 51,566 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.